198 related articles for article (PubMed ID: 25752847)
1. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.
Trenchevska O; Schaab MR; Nelson RW; Nedelkov D
Methods; 2015 Jun; 81():86-92. PubMed ID: 25752847
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Quantification of Apolipoprotein C-III
Kim H; Cheon DH; Yang WS; Baek JH
J Proteome Res; 2023 Jan; 22(1):91-100. PubMed ID: 36412001
[TBL] [Abstract][Full Text] [Related]
3. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.
Koska J; Yassine H; Trenchevska O; Sinari S; Schwenke DC; Yen FT; Billheimer D; Nelson RW; Nedelkov D; Reaven PD
J Lipid Res; 2016 May; 57(5):894-905. PubMed ID: 26945091
[TBL] [Abstract][Full Text] [Related]
4. Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis.
Koska J; Furtado J; Hu Y; Sinari S; Budoff MJ; Billheimer D; Nedelkov D; McClelland RL; Reaven PD
J Lipid Res; 2022 Sep; 63(9):100263. PubMed ID: 35952903
[TBL] [Abstract][Full Text] [Related]
5. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.
Yassine HN; Trenchevska O; Ramrakhiani A; Parekh A; Koska J; Walker RW; Billheimer D; Reaven PD; Yen FT; Nelson RW; Goran MI; Nedelkov D
PLoS One; 2015; 10(12):e0144138. PubMed ID: 26633899
[TBL] [Abstract][Full Text] [Related]
6. Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.
Nedelkov D
Proteomes; 2017 Oct; 5(4):. PubMed ID: 29036931
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.
Trenchevska O; Nelson RW; Nedelkov D
Bioanalysis; 2016 Aug; 8(15):1623-1633. PubMed ID: 27396364
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach.
Flood-Nichols SK; Tinnemore D; Wingerd MA; Abu-Alya AI; Napolitano PG; Stallings JD; Ippolito DL
Mol Cell Proteomics; 2013 Jan; 12(1):55-64. PubMed ID: 23059768
[TBL] [Abstract][Full Text] [Related]
9. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
10. Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.
Trenchevska O; Sherma ND; Oran PE; Reaven PD; Nelson RW; Nedelkov D
J Proteomics; 2015 Feb; 116():15-23. PubMed ID: 25549571
[TBL] [Abstract][Full Text] [Related]
11. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein.
Bondarenko PV; Cockrill SL; Watkins LK; Cruzado ID; Macfarlane RD
J Lipid Res; 1999 Mar; 40(3):543-55. PubMed ID: 10064743
[TBL] [Abstract][Full Text] [Related]
12. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
Olivieri O; Chiariello C; Martinelli N; Castagna A; Speziali G; Girelli D; Pizzolo F; Bassi A; Cecconi D; Robotti E; Manfredi M; Conte E; Marengo E
Clin Chem Lab Med; 2018 Aug; 56(9):1542-1550. PubMed ID: 29652662
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL).
Yamazaki A; Ohkawa R; Yamagata Y; Horiuchi Y; Lai SJ; Kameda T; Ichimura N; Tohda S; Tozuka M
Biol Chem; 2021 May; 402(4):439-449. PubMed ID: 33934596
[TBL] [Abstract][Full Text] [Related]
14. Complexity, cost, and content - three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing.
Nedelkov D; Hu Y
Clin Chem Lab Med; 2020 Jun; 58(6):858-863. PubMed ID: 31834860
[TBL] [Abstract][Full Text] [Related]
15. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays.
Cohen M; Yossef R; Erez T; Kugel A; Welt M; Karpasas MM; Bones J; Rudd PM; Taieb J; Boissin H; Harats D; Noy K; Tekoah Y; Lichtenstein RG; Rubin E; Porgador A
PLoS One; 2011 Jan; 6(1):e14540. PubMed ID: 21267442
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
Ooi EM; Chan DC; Hodson L; Adiels M; Boren J; Karpe F; Fielding BA; Watts GF; Barrett PH
Eur J Clin Invest; 2016 Aug; 46(8):730-6. PubMed ID: 27378472
[TBL] [Abstract][Full Text] [Related]
17. Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.
Moore D; McNeal C; Macfarlane R
Biochem Biophys Res Commun; 2011 Jan; 404(4):1034-8. PubMed ID: 21187063
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits.
Nicolay A; Lombard E; Arlotto E; Saunier V; Lorec-Penet AM; Lairon D; Portugal H
Clin Biochem; 2006 Sep; 39(9):935-41. PubMed ID: 16782082
[TBL] [Abstract][Full Text] [Related]
19. New Interface for Faster Proteoform Analysis: Immunoprecipitation Coupled with SampleStream-Mass Spectrometry.
Santos Seckler HD; Park HM; Lloyd-Jones CM; Melani RD; Camarillo JM; Wilkins JT; Compton PD; Kelleher NL
J Am Soc Mass Spectrom; 2021 Jul; 32(7):1659-1670. PubMed ID: 34043341
[TBL] [Abstract][Full Text] [Related]
20. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.
Mendoza S; Trenchevska O; King SM; Nelson RW; Nedelkov D; Krauss RM; Yassine HN
J Clin Lipidol; 2017; 11(1):224-233.e2. PubMed ID: 28391889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
